[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vasospastic-angina\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vasospastic-angina":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,92,137,164,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100639304","invasive-evaluation-and-phenotype-guided-treatment-of-anoca-in-women-100639304",false,"NCT07593157","Invasive Evaluation and Phenotype-Guided Treatment of ANOCA in Women","Invasive Functional and Morphological Coronary Assessment Followed by Phenotype-Guided Multidisciplinary Treatment in Women With Angina and Non-Obstructive Coronary Arteries: A Prospective Single-Center Interventional Study","ANOCA-UY","Inclusion Criteria:\n\n* Female participants aged 35 to 75 years.\n* Symptoms compatible with stable angina or suspected myocardial ischemia.\n* Non-obstructive coronary arteries, defined as absence of angiographic stenosis greater than or equal to 50%.\n* Ability to undergo invasive coronary assessment and clinical follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Significant structural heart disease.\n* Severe left ventricular systolic dysfunction, defined as left ventricular ejection fraction \\\u003C40%.\n* Clinically relevant contraindication to adenosine or acetylcholine, including severe asthma, untreated high-grade atrioventricular block, or known hypersensitivity.\n* Active oncological disease or life expectancy less than 12 months.\n* Inability to complete the diagnostic or therapeutic study protocol.\n* Participation in another clinical study that could interfere with the present protocol.","FEMALE","35 Years","75 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This prospective single-center interventional study will include women with angina and non-obstructive coronary arteries. Participants will undergo a standardized invasive coronary assessment combining coronary physiology, acetylcholine provocation testing, and optical coherence tomography. The diagnostic protocol will identify functional and morphological mechanisms of angina, including microvascular dysfunction, epicardial vasospasm, microvascular spasm, endothelial dysfunction, functional epicardial disease, combined mechanisms, or normal coronary physiology.\n\nBased on the identified phenotype, participants will receive individualized multidisciplinary treatment, including targeted pharmacological therapy, adapted cardiovascular rehabilitation, and psycho-emotional support when indicated. Clinical follow-up will be performed at 1, 6, and 12 months to assess angina symptoms, quality of life, functional capacity, adherence to treatment, and cardiovascular events.",[28,29,30],"ANOCA - Angina With Non-obstructive Coronary Arteries","Coronary Microvascular Dysfunction (CMD)","Vasospastic Angina",[32,33,34,35,36],"Angina with non-obstructive coronary arteries","ANOCA","INOCA","Vasospastic angina","Coronary Microvascular Dysfunction","NOT_YET_RECRUITING","2026-05-15",{"date":40,"type":41},"2026-05-18","ACTUAL",{"date":38,"type":22},{"date":44,"type":22},"2029-04-30",{"name":46,"class":47},"Hospital de Clínicas Dr. Manuel Quintela","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":72,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100414271","icormica---stratified-medicine-in-angina-100414271","NCT04674449","iCorMicA - Stratified Medicine in Angina","International Study of Coronary Microvascular Angina (iCorMicA): a Randomised, Controlled, Multicentre Trial and Registry","iCorMicA","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. A clinical plan for invasive coronary angiography.\n3. Symptoms of angina (typical or atypical) according to the Rose- and\u002For Seattle Angina questionnaires.\n4. Able to comply with study procedures.\n5. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. A non-coronary primary indication for invasive angiography (e.g. valve disease, heart failure).\n2. History of coronary artery bypass surgery.\n3. Presence of obstructive disease evident in a main coronary artery (diameter \\>2.5 mm), i.e. a coronary stenosis \\>50% and\u002For a fractional flow reserve (FFR) ≤0.80\\*.\n4. Logistical reason\\*. \\*These patients will enter a follow-up registry.","ALL","18 Years",{"count":60,"type":22},1500,[25],"The iCorMicA study is a multicentre, prospective, randomised, double-blind, sham-controlled, parallel-group, end-point trial and registry. The investigators seek to determine whether stratified medical therapy guided by an adjunctive interventional diagnostic procedure (IDP) during the invasive management of patients with known or suspected angina but no obstructive coronary artery disease improves symptoms, wellbeing, cardiovascular risk and clinical outcomes.",[64,65,66,29,67,68,69,30,70,71],"Microvascular Angina","Angina, Stable","Ischemia With No Obstructive Coronary Arteries (INOCA)","Ischaemic Heart Disease","Non-Obstructive Coronary Atherosclerosis","Coronary Artery Disease","Coronary; Ischemic","Angina Attacks",[73,74,75,76,77,78,79,80],"angina","microvascular angina","ischaemia with no obstructive coronary artery disease (INOCA)","stratified medicine","clinical trial","outcomes research","prognosis","health economics","RECRUITING","2026-04-03",{"date":84,"type":41},"2026-04-09",{"date":86,"type":41},"2020-12-30",{"date":88,"type":22},"2030-12-31",{"name":90,"class":47},"NHS Greater Glasgow and Clyde",39,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":116,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":48},"100608041","polish-registry-of-cardioneuroablation-and-cardioneuromodulation-100608041","NCT07196397","POLish Registry of CArdioneuroablation and CArdioneuromodulation","POL-CA Registry: Multicenter Observational Study of Neuromodulatory Procedures in Cardiovascular Autonomic Dysfunction Syndromes","POL-CA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of at least one of the following conditions:\n\n  * Inappropriate sinus tachycardia (IST)\n  * Postural orthostatic tachycardia syndrome (POTS)\n  * Vasovagal syncope (VVS)\n  * Cardioinhibitory carotid sinus syndrome (CSS)\n  * Symptomatic sinus bradycardia or functional AV block\n  * Orthostatic hypotension (OH)\n* History of recurrent autonomic symptoms (e.g., syncope, bradycardia, palpitations, orthostatic intolerance)\n* Undergoing or previously underwent interventional treatment affecting cardiac autonomic innervation (e.g., cardioneuroablation, SN-sparing ablation, cardiac sympathetic denervation)\n* Provided written informed consent (for prospective arm)\n\nExclusion Criteria:\n\n* Structural heart disease requiring surgical intervention\n* Permanent pacemaker or ICD implanted prior to enrollment\n* Inability to complete follow-up assessments or questionnaires\n* Severe psychiatric comorbidities impairing participation\n* Participation in another interventional clinical trial",{"count":101,"type":22},1000,"3 Years","OBSERVATIONAL","The multicentre observational study POL-CA involves a wide spectrum of patients with a history of syncopy. The study recruits patients with diagnosed vasovagal syndrome, cardioinhibitory carotid sinus syndrome, symptomatic sinus bradycardia or atrioventricular block, postural orthostatic tachycardia syndrome, orthostatic hypotension, and inappropriate sinus tachycardia syndrome. This is an observational, controlled study with retrospective, clinical data analysis of previously treated patients and the analysis of syncopal patients prospectively recruited into the study. The aim of the POL-CA registry is to create a platform for physicians to record treatment data for patients undergoing procedures that affect innervation or modify cardiovascular reflexes (cardioneuroablation, cardioneuromodulation) in order to provide a multicentre summary of population characteristics and treatment outcomes based on a standardized POL-CA questionnaire and methodology for various arrhythmias.",[106,107,108,109,110,111,30,64,112,113,114,115],"Vasovagal Syndrome VVS","Cardioinhibitory Carotid Sinus Syndrome CSS","Symptomatic Sinus Bradycardia SB or Atrioventricular Block AV","Postural Orthostatic Tachycardia Syndrome POTS","Orthostatic Hypotension","Inappropriate Sinus Tachycardia Syndrome IST","Ventricular Arrythmia","Raynaud Phenomena","Autonomic Dysfunction","Autonomic Diseases",[117,118,119,120,121,122,123,124,125,126],"cardioneuroablation","cardiac sympathetic denervation","sinoatrial node sparing hybrid ablation","catheter ablation","neural stimulation","cardioneuromodulation","percutaneus stellate ganglion blockage","cardiac rehabilitation","cardiovascular autonomic tests","syncope","2025-09-21",{"date":129,"type":41},"2025-09-29",{"date":131,"type":41},"2024-11-21",{"date":133,"type":22},"2031-12-31",{"name":135,"class":136},"SABAMED Medical Center Ltd.","NETWORK",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":145,"targetDuration":146,"studyType":103,"phases":4,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":48},"100600886","comprehensive-coronary-physiology-in-patients-with-angina-with-nonobstructive-coronary-arteries---czech-republic-100600886","NCT07103317","Comprehensive Coronary Physiology in Patients With Angina With Nonobstructive Coronary Arteries - Czech Republic","Comprehensive COROnary PHYSiology Assessment in Patients With Angina With Nonobstructive Coronary Arteries - CZECH Republic (CoroPhys-CZECH)","CoroPhys-CZ","Inclusion Criteria:\n\n* Adults of both sexes older than 18 years\n* Angina symptoms or angina equivalent\n* Referred to cath lab for evaluation of CAD\n* Invasive physiology testing performed (microcirculation testing +\u002F- vasospasm testing)\n\nExclusion Criteria:\n\n* Persons under the age of 18\n* Pregnant of nursing\n* No coronary physiology measurements were performed",{"count":101,"type":22},"100 Years","Coronary artery disease (CAD) is a leading cause of morbidity and mortality. While cardiologists have been focused on discrete, visible stenoses of coronary arteries, there is increasing awareness of the importance of microcirculation and vasospastic disorders in causing angina. The microvascular bed is composed of vessels smaller than 400 microns in diameter. Their network is significantly larger than that of the epicardial vessels and serves essential functions, including regulating myocardial blood flow and cellular metabolism.\n\nAngina pectoris, a most frequent symptom of CAD or myocardial ischemia, was assumed to be caused by significant stenosis of the epicardial coronary artery. However, it was found that in over 50% of cases, there was no obstructive CAD, which is described as angina with no obstructive coronary arteries (ANOCA) or ischemia with no obstructive coronary arteries (INOCA), according to the clinical setting.",[33,28,149,150,64,30,151],"MINOCA","Microvascular Dysfunction","Acetylcholine",[33,34,149,36,64,30,153,154],"Acetylcholine Testing","Coronary Termodilution","2025-08-01",{"date":157,"type":41},"2025-08-05",{"date":159,"type":41},"2023-04-20",{"date":161,"type":22},"2030-01-01",{"name":163,"class":47},"University Hospital, Motol",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":48},"100548733","phase-2-efficacy-of-targeted-medical-therapy-in-angina-and-nonobstructive-coronary-arteries-100548733","NCT06424834","Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries","A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study","MVP-ANOCA","Inclusion Criteria:\n\n* All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study.\n\nSpecific inclusion criteria for randomization:\n\n* Absence of significant epicardial coronary artery disease on angiography\n* Fractional flow reserve \\> 0.80\n\nAnd ≥ 1 of the following:\n\n* Epicardial coronary spasm on acetylcholine testing\n* Microvascular spasm on acetylcholine testing\n* Coronary flow reserve \\\u003C 2.5\n* Index of microcirculatory resistance ≥ 25\n* Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76\n\nExclusion Criteria:\n\n* Acute coronary syndrome less than one week prior to enrolment\n* Cardiomyopathy\n* Contraindications to beta-blockers or calcium channel blockers\n* Baseline systolic blood pressure \\\u003C 95 mmHg\n* Baseline heart rate \\\u003C 55 bpm",{"count":173,"type":22},150,[175,176],"PHASE2","PHASE3","The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing.\n\nParticipants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.",[179,64,30,180],"Angina Pectoris","Myocardial Bridge of Coronary Artery","2024-11-26",{"date":183,"type":41},"2024-11-27",{"date":185,"type":41},"2024-10-10",{"date":187,"type":22},"2026-12",{"name":189,"class":47},"Stanford University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":210,"locationsCount":48},"100426016","myocardial-ischemia-without-obstructive-coronary-stenoses-100426016","NCT04827498","Myocardial Ischemia Without Obstructive Coronary Stenoses","Myocardial Ischemia Without Obstructive Coronary Stenoses: A Prospective Observational Study With Invasive Coronary Pressure and Flow Measurements and Endothelial Function Test","Inclusion Criteria:\n\n* Written informed consent available.\n* Age ≥ 18 years.\n* Patient eligible for invasive physiological assessment with adenosine and \u002F or acetylcholine.\n\nExclusion Criteria:\n\n* Hemodynamic instability.\n* Anticipated technical issues for physiology wire measurements.\n* Culprit vessel of acute coronary syndrome\n* Contraindications for adenosine administration.\n* Contraindications for acetylcholine test.\n* Reduced life expectancy (less than 1 year).",{"count":198,"type":22},600,"Coronary-related myocardial ischemia can result from obstructive epicardial stenosis or non-obstructive causes including coronary microcirculatory dysfunction and vasomotor disorders. This prospective study has been created in order to provide knowledge in the field of non-obstructive coronary artery disease.",[201,68,202,30,203],"Myocardial Ischemia","Microvascular Coronary Artery Disease","Myocardial Bridging","2021-04-23",{"date":206,"type":41},"2021-04-26",{"date":208,"type":41},"2017-11-08",{"date":88,"type":22},{"name":211,"class":47},"Hospital San Carlos, Madrid"]